Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Gemcitabine With Curcumin for Pancreatic Cancer

This study has been completed.
Information provided by:
Rambam Health Care Campus Identifier:
First received: September 12, 2005
Last updated: September 21, 2010
Last verified: September 2010
The study hypotheasis is that curcumin, a natural compound with a potent antiproliferative effect, can improve the efficacy of the standard chemotherapy gemcitabine in patients with advanced pancreatic cancer. That is why the patients are given a daily oral dose of 8 gr of curcumin along the chemotherapeutic protocol of weekly gemcitabine.

Condition Intervention Phase
Pancreatic Cancer
Drug: curcumin (+ gemcitabine)
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase II Trial of Gemcitabine and Curcumin in Patients With Advanced Pancreatic Cancer

Resource links provided by NLM:

Further study details as provided by Rambam Health Care Campus:

Primary Outcome Measures:
  • time to tumor progression

Secondary Outcome Measures:
  • response rate
  • survival
  • clinical benefit
  • toxicity

Enrollment: 17
Study Start Date: July 2004
Study Completion Date: September 2010
Primary Completion Date: November 2007 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • locally advanced or metastatic adenocarcinoma of the pancreas
  • no prior chemotherapy
  • performance status 0-2
  • adequate hematology and chemistry

Exclusion Criteria:

  • serious concurrent medical condition
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00192842

Sponsors and Collaborators
Rambam Health Care Campus
Principal Investigator: Ron Epelbaum, MD
  More Information Identifier: NCT00192842     History of Changes
Other Study ID Numbers: RonCurcuminPancreas.CTIL 
Study First Received: September 12, 2005
Last Updated: September 21, 2010
Health Authority: Israel: Israeli Health Ministry Pharmaceutical Administration

Keywords provided by Rambam Health Care Campus:

Additional relevant MeSH terms:
Pancreatic Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Endocrine Gland Neoplasms
Digestive System Diseases
Pancreatic Diseases
Endocrine System Diseases
Antimetabolites, Antineoplastic
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Antiviral Agents
Anti-Infective Agents
Enzyme Inhibitors
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Anti-Inflammatory Agents
Antirheumatic Agents processed this record on October 25, 2016